Skip to content

US · PRFX · DRUG MANUFACTURERS - SPECIALTY & GENERIC

PRF Technologies Ltd. (PRFX) intrinsic value and stock valuation

$0.48as of 2026-11-21 · Mkt cap 88.59K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PRF Technologies Ltd. DCF and intrinsic value

InvestorsCraft values PRFX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PRFX’s statements →

PRF Technologies Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Tel Aviv, TA 6745442 painreform.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$20K
20172025
Net income
-$-4.84M
20172025
Free cash flow
-$-3.96M
20172025
Total equity
$9.29M-11% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$20K$0.00$0.00$90K$0.00
Operating income-$-4.99M-$-14.67M-$-9.58M-$-8.87M-$-7.21M
Net income-$-4.84M-$-14.59M-$-9.34M-$-8.79M-$-7.25M
EPSd-$-7.45M-$-729.5M———
Operating cash flow-$-3.96M-$-12.62M-$-6.68M-$-6.46M-$-6.55M
Capital expenditure-$0.00-$-10K-$-10K-$-10K-$-50K
Free cash flow-$-3.96M-$-12.63M-$-6.69M-$-6.46M-$-6.6M
Total assets$12M$4.53M$9.93M$12.3M$19.1M
Total debt$20K$40K$90K$0.00$0.00
Net debt-$-4.14M-$-4.22M-$-7.94M-$-4.1M-$-16.54M
Total equity$9.29M$1.82M$7.24M$11M$18.1M
Cash and short-term investments$4.17M$4.26M$8.03M$4.1M$16.5M
Income statement
20252024202320222021
Revenue$20K$0.00$0.00$90K$0.00
Cost of revenue$840K$20K$10K$10K$10K
Gross profit-$-830K-$-20K-$-10K$70K-$-10K
Research and development expenses$1.14M$11.7M$6.04M$4.42M$2.86M
Selling, general and administrative expenses$3.02M$2.95M$3.55M$4.45M$4.35M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$4.16M$14.7M$9.58M$8.87M$7.21M
Cost and expenses$5M-$-14.67M$9.58M$8.87M$7.21M
Interest income$120K$100K$410K$160K$0.00
Interest expense$10K$10K$380K$60K$10K
Depreciation and amortization$770K$20K$10K$10K$10K
Ebitda-$-4.21M-$-14.55M-$-9.57M-$-8.76M-$-7.2M
Operating income-$-4.99M-$-14.67M-$-9.58M-$-8.87M-$-7.21M
Total other income/expenses, net-$-30K$90K$250K$90K-$-30K
Income before tax-$-5.01M-$-14.58M-$-9.34M-$-8.78M-$-7.24M
Income tax expense$10K$10K$10K$10K$10K
Net income-$-4.84M-$-14.59M-$-9.34M-$-8.79M-$-7.25M
Weighted average shares outstanding$650K$20K$0.00$0.00$0.00
Weighted average diluted shares outstanding$650K$20K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$4.17M$4.26M$8.03M$4.1M$16.5M
Net receivables$140K$120K$40K$60K$220K
Inventory$0.00$0.00$0.00$7.82M$0.00
Total current assets$4.35M$4.43M$9.8M$12.3M$19M
Property, plant and equipment, net$60K$100K$130K$40K$50K
Goodwill and intangible assets$7.59M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.65M$100K$130K$40K$50K
Total assets$12M$4.53M$9.93M$12.3M$19.1M
Accounts payable$210K$300K$220K$210K$140K
Short-term debt$20K$90K$60K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.44M$2.44M$2.41M$1.06M$760K
Long-term debt$0.00$0.00$30K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$270K$260K$280K$240K$230K
Capital lease obligations$0.00$40K$90K$0.00$0.00
Total liabilities$2.71M$2.7M$2.69M$1.31M$990K
Common stock$0.00$0.00$150K$90K$90K
Retained earnings-$-61.29M-$-56.45M-$-41.86M-$-32.52M-$-23.73M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$0.00
Total equity$9.29M$1.82M$7.24M$11M$18.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$20K$40K$90K$0.00$0.00
Net debt-$-4.14M-$-4.22M-$-7.94M-$-4.1M-$-16.54M
Cash flow statement
20252024202320222021
Net income-$-5.02M-$-14.59M-$-9.34M-$-8.79M-$-7.25M
Depreciation and amortization$770K$20K$10K$10K$10K
Stock-based compensation$450K$310K$800K$1.39M$810K
Change in working capital-$-150K$1.66M$1.63M$670K-$-540K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-240K$80K$10K$70K-$-580K
Net cash provided by operating activities-$-3.96M-$-12.62M-$-6.68M-$-6.46M-$-6.55M
Investments in property, plant and equipment-$0.00-$-10K-$-10K-$-10K-$-50K
Acquisitions, net$20K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-980K-$-10K$5.99M-$-6.01M-$-50K
Common stock issued$3.82M$5.35M$1.7M$0.00$6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.82M$8.86M$4.62M$0.00$7.48M
Net change in cash-$-100K-$-3.77M$3.93M-$-12.46M$880K
Cash at end of period$4.17M$4.27M$8.04M$4.11M$16.6M
Operating cash flow-$-3.96M-$-12.62M-$-6.68M-$-6.46M-$-6.55M
Capital expenditure-$0.00-$-10K-$-10K-$-10K-$-50K
Free cash flow-$-3.96M-$-12.63M-$-6.69M-$-6.46M-$-6.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PRF Technologies Ltd.

        PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

        CEO
        Efraim Cohen-Arazi
        Employees
        7
        Beta
        1.05

        Explore

        Frequently asked questions

        What is the intrinsic value of PRF Technologies Ltd. (PRFX)?

        InvestorsCraft does not currently publish an intrinsic value for PRFX. How the IC value is calculated.

        Is PRFX undervalued?

        InvestorsCraft does not publish an undervaluation signal for PRFX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.